NMPA Approval Lung Cancer Immunotherapy: PD-1/PD-L1 Combo Trends 2025
This article delves into the NMPA's approval landscape for lung cancer immunotherapy, highlighting the emerging trends of PD-1/PD-L1 combination therapies by 2025.
Medically Reviewed
by Dr. James Morrison, Chief Medical Officer (MD, FACP, FACC)
Reviewed on: May 01, 2026
Key Takeaways
- Regulatory milestone: China's National Medical Products Administration (NMPA) has approved at least 20 PD-1/PD-L1 inhibitors by February 2025, creating a competitive environment for immunotherapy options in non-small cell lung cancer (NSCLC) treatment.
- Clinical trend: Recent NMPA approvals focus on combination regimens that pair PD-1/PD-L1 inhibitors with anti-angiogenesis agents or chemotherapy. This shift is backed by phase 3 trial data showing improved overall survival outcomes.
- Market implications: The trend toward combination therapies highlights a mature NSCLC treatment approach in China, with agents like sintilimab, camrelizumab, tislelizumab, toripalimab, atezolizumab, and durvalumab all competing for market share.
- Next steps: Ongoing regulatory emphasis on biosimilar development and cost-effective manufacturing will influence market access and adoption throughout the APAC region.
As of February 2025, China's National Medical Products Administration (NMPA) has approved over 20 PD-1 and PD-L1 inhibitors, significantly expanding immunotherapy options for lung cancer. This regulatory movement signals a strategic focus on combination therapies that merge immune checkpoint inhibitors with anti-angiogenesis agents or chemotherapy. Phase 3 clinical trials support this approach, showing improved overall survival for NSCLC patients. These approvals indicate a shift in NSCLC treatment in China, moving from monotherapy to combination strategies that confront various tumor escape mechanisms.
Drug Overview
PD-1 and PD-L1 inhibitors are monoclonal antibodies classified as immune checkpoint inhibitors. They function by blocking the interaction between programmed death-1 (PD-1) receptors on T cells and their ligands (PD-L1 and PD-L2) found on tumor cells, thus restoring anti-tumor immune responses. Approved PD-1 inhibitors in China include sintilimab, camrelizumab, tislelizumab, toripalimab, and pembrolizumab, while PD-L1 inhibitors consist of atezolizumab, durvalumab, and nivolumab (classified as anti-PD-1 despite some functional overlap). These agents are indicated for treating NSCLC, applicable to both early-stage and advanced disease, often used in combination with chemotherapy or anti-angiogenesis agents like bevacizumab or anlotinib.
The rationale for combination therapy is based on their complementary mechanisms: PD-1/PD-L1 inhibitors enhance T-cell immunity, while anti-angiogenesis agents decrease tumor blood vessel formation and may improve immune cell infiltration in the tumor microenvironment. Chemotherapy can also boost tumor antigen release, further enhancing immune recognition.
Clinical Insights
Phase 3 clinical trials that support recent NMPA approvals have shown significant improvements in overall survival (OS) with combination regimens compared to monotherapy or chemotherapy alone. While specific trial names and detailed efficacy metrics from individual studies are not disclosed in available regulatory summaries, the consistent approval of combination therapies reflects strong clinical evidence across several trial programs.
These trials typically assessed PD-1/PD-L1 inhibitors in combination with platinum-based chemotherapy (like carboplatin or cisplatin) or anti-angiogenesis agents (such as bevacizumab or anlotinib) in treatment-naïve patients with advanced NSCLC. The primary endpoint of overall survival was achieved in these studies, supporting the approvals. Combination regimens demonstrated sustained survival benefits over chemotherapy monotherapy, resulting in meaningful improvements in patient outcomes.
Safety profiles for these combination regimens were generally manageable, with immune-related adverse events (irAEs) being the main safety concern associated with PD-1/PD-L1 inhibitors. Grade 3 or higher irAEs, including pneumonitis, hepatitis, and colitis, occurred at expected frequencies based on prior immunotherapy experiences. Integrating chemotherapy or anti-angiogenesis agents did not significantly increase the incidence of serious adverse events beyond what each component would typically present, though careful monitoring and management of overlapping toxicities remained essential in clinical settings.
Regulatory Context
The NMPA has streamlined the approval process for PD-1/PD-L1 inhibitors for NSCLC through various regulatory pathways, including priority review and accelerated approval designations when applicable. By February 2025, the regulatory environment in China had advanced to encompass at least 20 approved agents in this category. The NMPA's approval strategy has increasingly leaned towards combination regimens, reflecting a shift in the agency's evaluation framework toward therapies that demonstrate superior efficacy through synergistic effects.
Recent approvals were supported by comprehensive phase 3 clinical trial data, with the NMPA emphasizing improved overall survival as the primary efficacy endpoint. The regulatory process for these agents generally involves the submission of extensive clinical dossiers, including preclinical safety data, pharmacology studies, and outcomes from multiple clinical trials conducted in both Chinese and international populations. Specific conditional versus full approval statuses and detailed submission timelines for individual agents are not publicly disclosed in current regulatory summaries.
The NMPA's approach aligns with broader regulatory trends in APAC markets, where accelerated pathways and priority review designations have become standard practices for advancing innovative oncology therapies. This strategy has allowed for quicker patient access to new treatments while upholding rigorous safety and efficacy standards.
Market Impact
The approval of over 20 PD-1/PD-L1 inhibitors has established a highly competitive market in China's lung cancer immunotherapy sector. Various domestic and international manufacturers are vying for market share, including those developing both originator agents and biosimilars. This competition significantly affects pricing and market access throughout the APAC region.
With hundreds of thousands of NSCLC patients diagnosed annually in China, the shift towards combination therapies broadens the treatment landscape, creating multiple pathways and allowing differentiation among competing agents. Companies focusing on combination regimens with innovative anti-angiogenesis agents or chemotherapy partners are strategically positioning themselves to capture market share through demonstrated clinical advantages.
Development and manufacturing of biosimilars have become critical in this competitive arena. As originator PD-1/PD-L1 inhibitors encounter biosimilar challengers, cost-effective manufacturing and regulatory pathways for biosimilar approvals will shape the market long-term. The cost-sensitive nature of APAC markets means that pricing strategies and manufacturing efficiency directly affect market penetration and patient access. Companies with strong manufacturing capabilities and favorable cost structures are better positioned to thrive in this growing segment.
Considerations regarding the reimbursement environment play a vital role. National health insurance programs and provincial reimbursement schemes in China increasingly demand health economic evidence demonstrating the cost-effectiveness of new therapies. Combination regimens that offer superior survival outcomes but come with higher total costs may face reimbursement hurdles unless supported by strong pharmacoeconomic data.
Future Outlook
The NMPA's approval landscape for PD-1/PD-L1 inhibitors is likely to evolve through 2025 and beyond, with a focus on several key areas:
- Bispecific antibodies and novel mechanisms: Next-generation immunotherapies that combine dual checkpoint inhibition or target alternative immune pathways are likely to enter the NMPA approval pipeline, potentially offering enhanced efficacy over current PD-1/PD-L1 monotherapy or dual PD-1/CTLA-4 inhibition approaches.
- Label expansions: Approved agents are expected to broaden their indications into earlier treatment settings, including adjuvant and neoadjuvant contexts, based on ongoing phase 3 trials. These expansions will widen the patient populations eligible for immunotherapy and increase market prospects.
- Biomarker-driven treatment selection: There is a growing focus on predictive biomarkers, including PD-L1 expression, tumor mutational burden, and emerging immune signatures, which will facilitate more personalized treatment decisions and potentially enhance clinical outcomes through better patient stratification.
- Biosimilar approvals: As originator PD-1/PD-L1 inhibitors near patent expiration or face biosimilar competition, the NMPA is expected to expedite biosimilar approvals, significantly influencing pricing and market access across APAC.
- Manufacturing and cost dynamics: Ongoing investments in manufacturing scale and process optimization will reduce production costs, enhancing patient access and market penetration in cost-sensitive APAC markets.
Key developments to monitor include regulatory submissions for bispecific antibodies targeting new immune checkpoints, anticipated phase 3 trial results for combination regimens in earlier treatment scenarios, and updates from the NMPA regarding biosimilar approval pathways, all of which will shape the competitive landscape in the next 12–24 months.
Frequently Asked Questions
What is the mechanism of action of PD-1/PD-L1 inhibitors?
PD-1 and PD-L1 inhibitors are monoclonal antibodies that prevent the interaction between programmed death-1 receptors on T cells and their ligands on tumor cells. This disruption of inhibitory signals allows the immune system to recognize and better eliminate cancer cells.
Why are combination regimens preferred over monotherapy in recent NMPA approvals?
Clinical trials have shown that combining PD-1/PD-L1 inhibitors with chemotherapy or anti-angiogenesis agents yields better overall survival outcomes than using either agent alone. The combination's synergistic mechanisms—immune activation alongside anti-angiogenesis or chemotherapy-induced tumor antigen release—target multiple tumor escape pathways, resulting in improved efficacy.
What are the key safety concerns with PD-1/PD-L1 inhibitor combination regimens?
The primary safety concern is immune-related adverse events (irAEs), including pneumonitis, hepatitis, colitis, and endocrinopathies. Grade 3 or higher irAEs occur at expected rates based on earlier immunotherapy experiences. The addition of chemotherapy or anti-angiogenesis agents necessitates careful monitoring of overlapping toxicities, though rates of serious adverse events typically do not exceed those anticipated from each component alone.
How many PD-1/PD-L1 inhibitors has the NMPA approved for NSCLC as of February 2025?
The NMPA has approved at least 20 PD-1/PD-L1 inhibitors as of February 2025, including sintilimab, camrelizumab, tislelizumab, toripalimab (PD-1 inhibitors), and atezolizumab, durvalumab (PD-L1 inhibitors), among others. This comprehensive portfolio reflects the agency's commitment to advancing immunotherapy for NSCLC treatment.
What role do biosimilars play in the future of the APAC lung cancer immunotherapy market?
Biosimilar development is expected to have a profound effect on pricing and market access across APAC. As originator PD-1/PD-L1 inhibitors face competition from biosimilars, the scale of manufacturing and efficient production will emerge as critical competitive factors. Biosimilar approvals will enhance patient access in cost-sensitive markets, especially in lower-income regions of APAC, while driving down overall treatment costs.
References
- National Medical Products Administration (NMPA). PD-1/PD-L1 Inhibitor Approval Portfolio for Non-Small Cell Lung Cancer Treatment. Regulatory Summary, February 2025.
Asia-Pacific Editor
Dr. Yuki Tanaka is an oncologist specializing in Asian pharmaceutical markets and regulatory harmonization. Former PMDA reviewer with expertise in bridging studies and ethnic factors....
![NMPA Priority Review Granted to [Drug Name] for Lung Cancer](/uploads/articles/nmpa-priority-review-drugname-lung-cancer-2024.webp)